Why Is Medication Preferred Over Surgery for Prolactinomas?
At a Glance
Medication is usually preferred for prolactinomas because dopamine agonists such as cabergoline often normalize prolactin and shrink the tumor, avoiding surgery and its risks. Surgery is considered when medication fails, causes severe side effects, or vision is threatened.
Hearing the word “tumor” naturally makes most people think of surgery. It is completely normal to wonder why your doctor wants to treat a mass with a medication instead of just taking it out. The answer is that prolactinomas are distinctive among pituitary tumors: they are highly sensitive to specific medications that not only stop them from producing excess hormones but also actively shrink the tumor mass. Because this medication works so well, surgery is usually kept as a backup option to avoid the risks of an operation.
The Power of Dopamine Agonists
Prolactinomas are usually benign (non-cancerous) growths. The medications used to treat them are called dopamine agonists, with cabergoline being the most commonly preferred choice [1] [2]. To understand how they work, it helps to know a bit about the tumor’s biology.
Prolactinoma cells express a high number of structures on their surface called dopamine D2 receptors [3] [4]. When you take a dopamine agonist, the medication binds directly to these receptors. This action sends a strong signal into the tumor cells that does two crucial things:
- Stops hormone production: It suppresses the tumor’s ability to release prolactin into your bloodstream [3].
- Shrinks the tumor: It disrupts the tumor cells’ growth signals, reducing their activity and volume, which physically shrinks the mass [5] [6].
High Success Rates
Medication is considered the standard first-line treatment because it is highly effective. Studies show that cabergoline can bring prolactin levels back to normal in 80% to 100% of microprolactinomas (tumors smaller than 10 millimeters) and 75% to 95% of macroprolactinomas (tumors 10 millimeters or larger) [7] [8].
In addition to normalizing hormone levels, the medication typically shrinks the tumor by more than half its original size, and sometimes makes it invisible on an MRI [7]. However, an invisible tumor on a scan does not guarantee a permanent cure; you will still need regular monitoring, and medication should only be reduced or stopped under medical supervision.
Because medication can achieve these results, it often avoids the need for transsphenoidal surgery (an operation usually performed through the nose) and its associated risks. These risks can include damage to the healthy pituitary gland, cerebrospinal fluid leaks, or the need for lifelong hormone replacement [9].
Medication Side Effects and Safety
While preferred over surgery, dopamine agonists are not risk-free. Common side effects include nausea, dizziness or lightheadedness from low blood pressure, headache, and fatigue. Less commonly, patients may experience clinically important impulse-control or behavioral changes. Depending on your dose and medical history, your doctor may also monitor your heart valves, though this is individualized based on the patient [9].
When is Surgery the Better Option?
While medication is the gold standard, transsphenoidal surgery remains a very important option. Your care team may recommend surgery instead of, or after trying, medication if:
- The medication isn’t working: About 10% of prolactinomas are resistant to dopamine agonists, meaning the tumor does not shrink or prolactin levels stay high despite treatment [10] [11].
- Severe side effects: Some people cannot tolerate the medication due to side effects, making long-term use impossible [9] [12].
- Immediate threat to your vision: If a large tumor is pressing against your optic chiasm (where the optic nerves cross) and causing vision loss, urgent specialist assessment is required. If vision is severely impaired or does not improve promptly with medication, surgery is often needed to relieve the pressure [13].
- The tumor is mostly fluid: Tumors with large fluid-filled spaces (cystic prolactinomas) sometimes do not shrink as well with medication, and surgery might be needed [14].
- Personal preference: For some people with well-contained microprolactinomas, surgery by an experienced pituitary surgeon may be discussed as a primary option if they strongly prefer the chance of surgical remission over taking medication for years [9] [15].
Even if you have surgery, it is important to know that for large or invasive tumors, the operation might not remove every single cell. You may still need to take medication afterward to keep any remaining cells in check [16] [17].
When to Seek Immediate Care
Pituitary apoplexy is a rare but serious event where the tumor suddenly bleeds or swells [13] [9]. Seek emergency medical care if you experience sudden severe headache, new vision loss, double vision, vomiting, or confusion. This is a medical emergency requiring immediate assessment, hormone evaluation, and sometimes urgent surgery.
Common questions in this guide
Why is medicine usually tried before surgery for a prolactinoma?
How does cabergoline shrink a prolactinoma?
When might surgery be recommended instead of medication?
What side effects can prolactinoma medication cause?
Does a prolactinoma stay gone if medicine makes it disappear on an MRI?
What are the risks of transsphenoidal surgery for a prolactinoma?
What symptoms mean I need emergency care with a prolactinoma?
Related questions
Show more
Get notified when new evidence is published on acquired hyperprolactinemia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (17)
- 1
The Role of Dopamine Agonists in Pituitary Adenomas.
Giraldi EA, Ioachimescu AG
Endocrinology and metabolism clinics of North America 2020; (49(3)):453-474 doi:10.1016/j.ecl.2020.05.006.
PMID: 32741482 - 2
Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism.
Vilar L, Abucham J, Albuquerque JL, et al.
Archives of endocrinology and metabolism 2018; (62(2)):236-263 doi:10.20945/2359-3997000000032.
PMID: 29768629 - 3
Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.
Pivonello C, Patalano R, Negri M, et al.
Frontiers in endocrinology 2021; (12()):791633 doi:10.3389/fendo.2021.791633.
PMID: 35095761 - 4
Dopamine Agonists for Pituitary Adenomas.
Cooper O, Greenman Y
Frontiers in endocrinology 2018; (9()):469 doi:10.3389/fendo.2018.00469.
PMID: 30186234 - 5
The Balance of PI3K and ERK Signaling Is Dysregulated in Prolactinoma and Modulated by Dopamine.
Roof AK, Jirawatnotai S, Trudeau T, et al.
Endocrinology 2018; (159(6)):2421-2434 doi:10.1210/en.2017-03135.
PMID: 29726995 - 6
Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively.
Tang C, Sun R, Wen G, et al.
Cell death & disease 2019; (10(5)):335 doi:10.1038/s41419-019-1526-0.
PMID: 31000722 - 7
Current approach to treatments for prolactinomas.
Tirosh A, Shimon I
Minerva endocrinologica 2016; (41(3)):316-23.
PMID: 26399371 - 8
Does DRD2 polymorphism influence the clinical characteristics of prolactinoma?
Ilhan M, Kahraman OT, Turan S, et al.
Annales d'endocrinologie 2015; (76(5)):614-9.
PMID: 26514951 - 9
Italian Guidelines for the Management of Prolactinomas.
Cozzi R, Simona Auriemma R, De Menis E, et al.
Endocrine, metabolic & immune disorders drug targets 2023; (23(12)):1459-1479 doi:10.2174/1871530323666230511104045.
PMID: 37171003 - 10
Treatment of Prolactinoma.
Inder WJ, Jang C
Medicina (Kaunas, Lithuania) 2022; (58(8)) doi:10.3390/medicina58081095.
PMID: 36013562 - 11
Prolactin-secreting adenomas: pathogenesis, diagnosis, and management.
Fleseriu M, Varlamov EV, Akirov A, et al.
The lancet. Diabetes & endocrinology 2025; (13(10)):874-890 doi:10.1016/S2213-8587(25)00227-X.
PMID: 40876473 - 12
[Indications for surgical treatment of prolactin-secreting pituitary adenomas].
Kalinin PL, Astaf'eva LI, Kadashev BA, Ismailov DB
Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko 2017; (81(5)):117-124 doi:10.17116/neiro2017815117-124.
PMID: 29076475 - 13
The Role of Surgery in the Management of Prolactinomas.
Donoho DA, Laws ER
Neurosurgery clinics of North America 2019; (30(4)):509-514 doi:10.1016/j.nec.2019.05.010.
PMID: 31471058 - 14
Significance of surgical management for cystic prolactinoma.
Ogiwara T, Horiuchi T, Nagm A, et al.
Pituitary 2017; (20(2)):225-230 doi:10.1007/s11102-016-0766-6.
PMID: 27757801 - 15
Surgery for prolactinomas: a better choice?
Honegger J, Nasi-Kordhishti I, Aboutaha N, Giese S
Pituitary 2020; (23(1)):45-51 doi:10.1007/s11102-019-01016-z.
PMID: 31853793 - 16
Surgical outcomes of medically failed prolactinomas: a systematic review and meta-analysis.
Yagnik KJ, Erickson D, Bancos I, et al.
Pituitary 2021; (24(6)):978-988 doi:10.1007/s11102-021-01188-7.
PMID: 34580821 - 17
Determinants of Surgical Remission in Prolactinomas: A Systematic Review and Meta-Analysis.
Wright K, Chaker L, Pacione D, et al.
World neurosurgery 2021; (154()):e349-e369 doi:10.1016/j.wneu.2021.07.035.
PMID: 34325023
This page is for informational purposes only and does not replace professional medical advice. Treatment decisions for a prolactinoma should be made with your endocrinologist and pituitary surgeon; seek emergency care for sudden severe headache or new vision changes.